MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

105.7

-0.57%↓

WBA

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

105.7

-0.57%↓

WBA

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

105.7

-0.57%↓

WBA

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

105.7

-0.57%↓

WBA

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

105.7

-0.57%↓

WBA

+0.09%↑

CHE

551.68

-1.39%↓

Начало・Списък с акции・BioNTech SE ADR

BioNTech SE ADR

Отворен

СекторЗдравеопазване

104 -10.45

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

113

Максимум

120.45

Ключови измерители
By Trading Economics
Приходи	143M 301M
Продажби	-55M 1.2B
EPS	1.08
Марж на печалбата	25.311
Служители	6,772
EBITDA	253M 464M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+22.03% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.6B 24B
Предишно отваряне	114.45
Предишно затваряне	104

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

99 / N/A Подкрепа & съпротива

BioNTech SE ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.02.2025 г., 18:52 ч. UTC

Значими двигатели на пазара

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15.11.2024 г., 10:28 ч. UTC

Значими двигатели на пазара

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

6.05.2024 г., 11:27 ч. UTC

Печалби

BioNTech Swings to Net Loss on Lower Covid Vaccine Sales

15.11.2024 г., 11:14 ч. UTC

Пазарно говорене

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15.11.2024 г., 10:34 ч. UTC

Пазарно говорене

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5.08.2024 г., 10:02 ч. UTC

Печалби

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5.08.2024 г., 10:01 ч. UTC

Печалби

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5.08.2024 г., 10:01 ч. UTC

Печалби

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5.08.2024 г., 10:00 ч. UTC

Печалби

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5.08.2024 г., 09:59 ч. UTC

Печалби

BioNTech 2Q Loss EUR807.8M >BNTX

5.08.2024 г., 09:59 ч. UTC

Печалби

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5.08.2024 г., 09:59 ч. UTC

Печалби

BioNTech 2Q Rev EUR128.7M >BNTX

6.05.2024 г., 20:15 ч. UTC

Печалби

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come -- IBD

6.05.2024 г., 10:47 ч. UTC

Печалби

BioNTech Sees FY24 Rev EUR2.5B-EUR3.1B >BNTX

6.05.2024 г., 10:46 ч. UTC

Печалби

Correct: BioNTech 1Q Loss/Shr EUR1.31 >BNTX

6.05.2024 г., 10:46 ч. UTC

Печалби

Correct: BioNTech 1Q Loss EUR315.1M >BNTX

6.05.2024 г., 10:46 ч. UTC

Печалби

Correct: BioNTech 1Q Rev EUR187.6M >BNTX

6.05.2024 г., 10:45 ч. UTC

Печалби

BioNTech 1Q Rev $187.6M >BNTX

6.05.2024 г., 10:45 ч. UTC

Печалби

BioNTech 1Q Loss $315.1M >BNTX

6.05.2024 г., 10:45 ч. UTC

Печалби

BioNTech 1Q Loss/Shr $1.31 >BNTX

Сравнение с други в отрасъла

Ценова промяна

BioNTech SE ADR Прогноза

Ценова цел

By TipRanks

22.03% нагоре

12-месечна прогноза

Среден 140.13 USD 22.03%

Висок 171 USD

Нисък 110 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за BioNTech SE ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

Купи

Задържане

Продай

Според 17 анализатори, дали борсови рейтинги на BioNTech SE ADR през последните 3 месеца.

Техническа оценка

By Trading Central

99 / N/AПодкрепа & съпротива

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac